title: Nivolumab for squamous-cell non-small-cell lung cancer.
authors.forename: Farhat
authors.initials: F
authors.lastname: Yaqub
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D015142:Baltimore; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000473:pathology; D000077594:Nivolumab; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D000077143:Docetaxel; D000077594:Nivolumab; D043823:Taxoids